| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the New Jersey Medical School (Dr. Cook, J.R. Quinless, and A. Jotkowitz) and the School of Nursing (Dr. Beaton), University of Medicine and Dentistry of New Jersey, Newark.
Address correspondence to Dr. Stuart D. Cook, University of Medicine and Dentistry of New Jersey, 65 Bergen Street, Room 1535, Newark, NJ 07107-3001; e-mail: cooksd{at}umdnj.edu
Objective:— To determine levels of serum interferon beta (IFNß) neutralizing antibody (NAb) and neopterin—an IFN biologic response marker—in patients with MS treated with Betaseron or Avonex.
Background:— Controversy exists over the relative immunogenicity of IFNß-1a and IFNß-1b and the reasons for any such difference. To determine the role of patient profile and test methodology in IFNß, NAb levels need to be measured blindly and simultaneously in a predefined closely matched MS patient cohort.
Methods:— Serum NAb and neopterin levels were measured in closely matched patients on Avonex (n = 98) or Betaseron (n = 64). NAb were determined by Athena Diagnostics and serum neopterin levels by Covance Laboratories using a competitive binding radioimmunoassay.
Results:— More patients taking Betaseron (22%) than Avonex (7%) had elevated titers of NAb (p = 0.008). Mean serum neopterin levels were lower in patients with high as compared to low NAb titers (p = 0.0002). No difference in mean neopterin levels was found comparing the total Betaseron group to the Avonex group; however, in the subset of patients with low NAb titers, mean neopterin levels were higher in the Betaseron than in the Avonex group (p = 0.027). A random cross-sectional sampling of patients on Avonex showed a decrease in neopterin levels over time between weekly doses.
Conclusion:— NAb are more commonly found with Betaseron than Avonex. More studies are needed to determine the correlation among serum neopterin levels, other biologic response markers, NAb, and disease activity in patients with MS being treated with IFNß.
This article has been cited by other articles:
|
|
 |
|
  A. R. Pachner, J. D. Warth, A. Pace, S. Goelz, and On behalf of the INSIGHT investigators Effect of neutralizing antibodies on biomarker responses to interferon beta: The INSIGHT study Neurology, November 3, 2009; 73(18): 1493 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Soelberg Sorensen Review: Neutralizing antibodies against interferon-beta Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 125 - 141. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Sorensen, N Koch-Henriksen, E. Flachs, and K Bendtzen Is the treatment effect of IFN-{beta} restored after the disappearance of neutralizing antibodies? Multiple Sclerosis, July 1, 2008; 14(6): 837 - 842. [Abstract] [PDF]
|
|
|
|
|
|
R. A Farrell and G. Giovannoni Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis Multiple Sclerosis, June 1, 2007; 13(5): 567 - 577. [Abstract] [PDF]
|
|
|
|
|
|
J. Oger and E. Gibbs Binding antibodies: Vancouver's perspective Multiple Sclerosis, May 1, 2007; 13(1_suppl): 36 - 43. [Abstract] [PDF]
|
|
|
|
|
|
P. S. Sorensen, T. Tscherning, H. K. Mathiesen, A. R. Langkilde, C. Ross, M. Ravnborg, and K. Bendtzen Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology, November 14, 2006; 67(9): 1681 - 1683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Francis, G. P.A. Rice, J. C. Alsop, and for the PRISMS (Prevention of Relapses and Disabil Interferon {beta}-1a in MS: Results following development of neutralizing antibodies in PRISMS Neurology, July 12, 2005; 65(1): 48 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Sorensen, N. Koch-Henriksen, C. Ross, K. M. Clemmesen, K. Bendtzen, and the Danish Multiple Sclerosis Study Group Appearance and disappearance of neutralizing antibodies during interferon-beta therapy Neurology, July 12, 2005; 65(1): 33 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Scagnolari, M. Casato, F. Bellomi, F. De Pisa, O. Turriziani, R. Coviello, M. R. Pirro, F. Dianzani, and G. Antonelli Serum Interferon (IFN)-Neutralizing Antibodies and Bioactivities of IFNs in Patients with Severe Type II Essential Mixed Cryoglobulinemia Clin. Vaccine Immunol., January 1, 2003; 10(1): 70 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Giovannoni, F E Munschauer 3rd, and F Deisenhammer Neutralising antibodies to interferon beta during the treatment of multiple sclerosis J. Neurol. Neurosurg. Psychiatry, November 1, 2002; 73(5): 465 - 469. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
